FDA lifts clinical hold on Rocket's gene therapy for heart failure after 3-month delay

Kyle Blankenship

New Jersey’s Rocket Pharmaceuticals hit a major roadblock for its AAV-delivered gene therapy for heart failure in May after the FDA came asking for more …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA lifts clinical hold on Rocket's gene therapy for heart failure after 3-month delay

Kyle Blankenship

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

FDA lifts clin­i­cal hold on Rock­et's gene ther­a­py for heart fail­ure af­ter 3-month de­lay

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

FDA lifts clinical hold on Rocket's gene therapy for heart failure after 3-month delay